{"id":"W2804085823","doi":"10.1016/s2213-2600(18)30201-7","title":"Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trial","year":2018,"lang":"en","type":"article","venue":"The Lancet Respiratory Medicine","topic":"Asthma and respiratory diseases","field":"Medicine","cited_by":133,"is_retracted":false,"has_abstract":false,"ca_institutions":"AstraZeneca (Canada); McGill University Health Centre; University of British Columbia","funders":"Medical Research Council; Odense Universitetshospital; University of Leicester; National Institute for Health and Care Research; NIHR Great Ormond Street Hospital Biomedical Research Centre; GlaxoSmithKline; Asthma and Lung UK; AstraZeneca","keywords":"Medicine; Placebo; Asthma; Mepolizumab; Monoclonal antibody; Eosinophilic; Double blind; Interleukin 5; Internal medicine; Eosinophilic esophagitis; Gastroenterology; Inflammation; Monoclonal; Interleukin; Immunology; Antibody; Pathology; Eosinophil; Cytokine; Disease; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004415023,0.0007085375,0.003046219,0.0007419764,0.0002361368,0.00004569919,0.0004919515,0.0002759406,0.0002848532],"category_scores_gemma":[0.00113026,0.0003971762,0.0003837548,0.0006688538,0.0005581349,0.0002585033,0.00005954654,0.0006677526,0.00004562306],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001997026,"about_ca_system_score_gemma":0.0003446329,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00009095127,"about_ca_topic_score_gemma":0.0001915599,"domain_scores_codex":[0.9937609,0.001954228,0.001718825,0.000759416,0.0009980852,0.0008085287],"domain_scores_gemma":[0.9960607,0.001303327,0.000674392,0.001091836,0.000325682,0.0005441217],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9384848,0.0006130252,0.0003076927,0.0002003043,0.0002317254,0.0001321944,0.001372816,0.000735845,0.041721,0.00005706365,0.000391605,0.01575192],"study_design_scores_gemma":[0.9331827,0.03266994,0.0004941149,0.001135451,0.0004948324,0.00002001587,0.0001668317,0.006143836,0.02391886,0.00001577007,0.001405405,0.0003522434],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.984304,0.0004641619,0.00009313021,0.001578403,0.000645383,0.0111727,0.00002041701,0.0001240425,0.001597767],"genre_scores_gemma":[0.9902774,0.00001795311,0.00002114286,0.001834507,0.006977503,0.0006177519,0.00006367173,0.00007793478,0.0001121283],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03205692,"threshold_uncertainty_score":0.999848,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03919430931402542,"score_gpt":0.3744604178185523,"score_spread":0.3352661085045269,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}